Septerna, Inc. Earnings Per Share (Diluted)
Septerna, Inc. (SEPN) reported Earnings Per Share (Diluted) of -$0.29 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareDiluted · last filed 2026-08-10
- Septerna, Inc. earnings per share, diluted for the quarter ending 2026-06-30 was -$0.29.
- Septerna, Inc. earnings per share, diluted for the quarter ending 2026-03-31 was -$0.19.
- Septerna, Inc. earnings per share, diluted for the quarter ending 2025-09-30 was $0.18.
- Septerna, Inc. earnings per share, diluted for the quarter ending 2025-06-30 was -$0.56.
- Septerna, Inc. earnings per share, diluted for fiscal 2025 was -$1.10.
- Septerna, Inc. earnings per share, diluted for fiscal 2024 was -$7.26, a 2603.45% decline from fiscal 2023.
- Septerna, Inc. earnings per share, diluted for fiscal 2023 was $0.29.
| Period end | Earnings Per Share, Diluted 3 month | Earnings Per Share, Diluted 6 month | Earnings Per Share, Diluted 9 month | Earnings Per Share, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.29 10-Q · filed 2026-08-10 | -$0.48 10-Q · filed 2026-08-10 | ||
| 2026-03-31 | -$0.19 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | -$1.10 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.18 10-Q · filed 2025-11-10 | -$0.86 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | -$0.56 10-Q · filed 2026-08-10 | -$1.05 10-Q · filed 2026-08-10 | ||
| 2025-03-31 | -$0.49 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$7.26 10-K · filed 2026-03-09 | |||
| 2024-09-30 | -$8.40 10-Q · filed 2025-11-10 | -$21.87 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | -$7.03 10-Q · filed 2025-08-11 | -$13.40 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$6.35 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $0.29 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$5.45 10-Q · filed 2024-11-20 | -$16.49 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |